文献速递慢性肾脏病肾血管病与高血压

Vicadrostat/恩格列净在不同CKD严重程度/高血压状态下的事后分析

Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status.
PubMed 文献 · Kidney Int Rep · 2026-04-16

这项2期试验事后分析纳入503名有基线和第14周UACR数据的CKD患者,评估醛固酮合成酶抑制剂vicadrostat单用或联用恩格列净对白蛋白尿的影响。结果显示,无论KDIGO风险分组、KFRE亚组、是否控制不佳的高血压或是否使用利尿剂,UACR降低均一致。

要点

  • Vicadrostat单用或联用恩格列净在各CKD严重程度亚组中均降低UACR
  • 10mg和20mg vicadrostat的UACR降幅为25%-55%,与总体研究24%-51%一致
  • 疗效不受KDIGO风险、KFRE风险、高血压控制状态或利尿剂使用影响

核心结论

  • Vicadrostat降低白蛋白尿的效应在不同CKD分期、肾脏风险评分、高血压状态及利尿剂使用情况下总体一致。

研究设计与样本

  • 2期试验(NCT05182840)的事后分析,纳入503名有基线和第14周UACR数据的CKD患者。

主要发现

  • 10mg和20mg vicadrostat剂量组UACR校正平均降幅为25%-55%,总体研究为24%-51%。
  • 亚组包括KDIGO中高风险与极高风险、KFRE 5年风险<5%与≥5%、有无未控制高血压及基线利尿剂使用。

关键数值与推荐

  • 未控制高血压定义为血压≥140/90 mmHg且使用≥2类降压药。
  • KFRE 4因子5年风险<5% versus ≥5%;KDIGO中高风险 versus 极高风险。

临床怎么用

  • 对于不同CKD严重程度和高血压状态的患者,vicadrostat降低白蛋白尿的效应可能一致,但需结合个体情况。

局限性

  • 事后分析,样本量503例,结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This phase 2 trial (NCT05182840) assessed the efficacy and safety of the aldosterone synthase inhibitor, vicadrostat, alone or with empagliflozin, in people with chronic kidney disease (CKD). These post hoc analyses assessed the effects of vicadrostat, with or without background empagliflozin, on albuminuria across a range of CKD severity and hypertension (HTN) status. METHODS: The analysis set included 503 participants who had urine albumin-to-creatinine ratio (UACR) measures available at baseline and week 14. Subgroup analyses of the effects of vicadrostat, given alone or with empagliflozin, were performed by the presence or absence of uncontrolled HTN (defined as blood pressure [BP] ≥ 140/90 mm Hg and use of ≥2 classes of antihypertensive medication), kidney failure risk equation (KFRE) 4-factor 5-year risk < 5% versus ≥ 5%, Kidney Disease: Improving Global Outcomes (KDIGO) moderate-to-high risk versus very high risk, and diuretic use at baseline. RESULTS: UACR was reduced with vicadrostat, with or without empagliflozin background, across all subgroup analyses (adjusted mean reduction with 10 mg and 20 mg vicadrostat dose groups: 25%-55% vs. 24%-51% in the overall study). UACR reductions were consistent in participants irrespective of KDIGO risk group, KFRE subgroup, presence or absence of uncontrolled HTN at baseline or diuretic use. CONCLUSION: The effects of vicadrostat on albuminuria reduction, with or without empagliflozin, were generally consistent irrespective of CKD stage and kidney risk as scored using KDIGO or the KFRE, HTN status, or use of diuretics.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Correa-Rotter R, Rossing P, Canziani ME, et al. Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status. Kidney Int Rep. 2026. PMID: 42292647. doi:10.1016/j.ekir.2026.106545

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。